OTCMKTS:CNBX CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis $0.0070 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.0060▼$0.007550-Day Range$0.0057▼$0.011052-Week Range$0.01▼$0.05Volume120,003 shsAverage Volume239,418 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get CNBX Pharmaceuticals alerts: Email Address Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About CNBX Pharmaceuticals Stock (OTCMKTS:CNBX)CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.Read More CNBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNBX Stock News HeadlinesNovember 24, 2023 | benzinga.comCNBX Pharmaceuticals Stock (OTC:CNBX) Dividends: History, Yield and DatesNovember 5, 2023 | morningstar.comCNBX Pharmaceuticals Inc CNBXJuly 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.October 10, 2023 | investing.comCNBX Historical DataJuly 28, 2023 | finance.yahoo.comCNBX - CNBX Pharmaceuticals Inc.November 8, 2022 | benzinga.comCNBX Acquires A Controlling Interest In Cancer Immunotherapy DeveloperNovember 8, 2022 | finance.yahoo.comCNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza BiopharmaOctober 18, 2022 | finance.yahoo.comCNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer TherapyJuly 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.October 13, 2022 | finance.yahoo.comCNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and IsraelSeptember 28, 2022 | finance.yahoo.comCNBX Pharmaceuticals Announces New Patent Granted in AustraliaSeptember 12, 2022 | reuters.comCNBX Pharmaceuticals IncAugust 16, 2022 | ca.finance.yahoo.comCNBX Pharmaceuticals Inc. (CNBX)June 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Earnings Estimates, EPS, and RevenueJune 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Analyst Ratings, Price Targets, PredictionsJune 7, 2022 | finance.yahoo.comCNBX Pharmaceuticals Inc. (CNBXD)May 31, 2022 | finance.yahoo.comCNBX Pharmaceuticals Release a New Corporate PresentationMay 14, 2022 | barrons.comCNBX Pharmaceuticals Inc.See More Headlines Receive CNBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryCannabis Current SymbolOTCMKTS:CNBX CUSIPN/A CIK1343009 Webwww.cannabics.com Phone(877) 424-2429FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Gabriel Yariv (Age 48)President, COO & Executive Chairman Comp: $241.67kMr. Uri Ben-Or CPA (Age 54)CPA, M.B.A., MBA, Chief Financial Officer Comp: $40.32kMr. Eyal Barad (Age 59)Co-Founder, CEO & Director Comp: $269.15kDr. Sanja Goldberg (Age 48)Chief Technology Officer Comp: $48.12kNoam PermontVice President of Public Relations & Investor RelationsDr. Sigalit Ariely-Portnoy Ph.D. (Age 60)Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board Dr. Tal Mofkadi Ph.D.Financial Advisor & Member of Advisory BoardMr. Yasha Borstein (Age 61)Chief Data Officer Dr. Yaakov Waksman (Age 72)Head of Cannabidiol Research Dr. Ilya Reznik M.D.Head of Neuropsychiatry DevelopmentMore ExecutivesKey Competitors1PM IndustriesOTCMKTS:OPMZAcquired SalesOTCMKTS:AQSPAmerican CannabisOTCMKTS:AMMJAmeriCannOTCMKTS:ACANCannabis SativaOTCMKTS:CBDSView All Competitors CNBX Stock Analysis - Frequently Asked Questions How have CNBX shares performed this year? CNBX Pharmaceuticals' stock was trading at $0.0142 on January 1st, 2024. Since then, CNBX shares have decreased by 50.7% and is now trading at $0.0070. View the best growth stocks for 2024 here. When did CNBX Pharmaceuticals' stock split? Shares of CNBX Pharmaceuticals reverse split on Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of CNBX Pharmaceuticals? Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CNBX Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CNBX Pharmaceuticals investors own include Organigram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF) and American Cannabis (AMMJ). This page (OTCMKTS:CNBX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNBX Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNBX Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.